Design and quality considerations for randomized controlled trials in systemic sclerosis

dc.contributor.authorKyriakidi, M.en
dc.contributor.authorIoannidis, J. P.en
dc.date.accessioned2015-11-24T19:25:10Z
dc.date.available2015-11-24T19:25:10Z
dc.identifier.issn0004-3591-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/22582
dc.rightsDefault Licence-
dc.subjectDatabases, Factualen
dc.subjectDouble-Blind Methoden
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectQuality Controlen
dc.subjectRandomized Controlled Trials as Topic/*methods/standardsen
dc.subjectResearch Design/standards/*trendsen
dc.subjectSample Sizeen
dc.subjectScleroderma, Systemic/*therapyen
dc.subjectTime Factorsen
dc.titleDesign and quality considerations for randomized controlled trials in systemic sclerosisen
heal.abstractOBJECTIVE: To appraise systematically randomized controlled trials (RCTs) on systemic sclerosis (SSc) in order to determine whether the parameter of study design and its quality may influence the reporting of efficacy for tested interventions. METHODS: Seventy RCTs were analyzed (1965-2000) in terms of design, patient characteristics, outcomes, and reported results. RESULTS: Median sample size was 28 patients. Fifty-nine trials were double blind, but only 16 mentioned the randomization mode and only 7 described allocation concealment. There was sufficient information on withdrawals in 37 trials. Larger trials with longer followup scored higher on quality characteristics, but had higher withdrawal rates. Only 8 trials had a followup of more than 1 year. Significant efficacy was less likely to be reported in double-blind studies (P = 0.029) and in studies with larger rates of withdrawal (P = 0.032). Specification of the following parameters improved over time: power calculations (P = 0.0003), outcomes (P = 0.001), and sample size per arm (P = 0.011). CONCLUSIONS: Several aspects of the quality of design and conduct of SSc RCTs can be improved. Adequately powered trials with longer followup and clear outcomes are needed.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/11932881-
heal.journalNameArthritis Rheumen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2002-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Φόρτωση...
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή: